Claims for Patent: 8,906,373

Summary for Patent: 8,906,373

Title:	Use of TNF-alpha inhibitor for treatment of psoriasis
Abstract:	The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s):	Banerjee; Subhashis (Shrewsbury, MA), Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Taylor; Lori K. (Boston, MA), Spiegler; Clive E. (Skillman, NJ), Tracey; Daniel E. (Hamilton, BM), Chartash; Elliot K. (Marietta, GA), Barchuk; William T. (Madison, NJ), Yan; Philip (Vernon Hills, IL), Murtaza; Anwar (North Grafton, MA), Salfeld; Jochen G. (North Grafton, MA), Fischkoff; Steven A. (Short Hills, NC), Granneman; George R. (Marco Island, FL)
Assignee:	AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:	14/266,598
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,906,373
Patent Claims:	1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has .gtoreq.3 swollen and .gtoreq.3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment. 2. The method of claim 1, wherein said patient has psoriasis in <3% body surface area prior to the treatment. 3. The method of claim 1, wherein said patient has psoriasis in .gtoreq.3% body surface area prior to the treatment. 4. A method for treating chronic plaque psoriasis, comprising subcutaneously administering to a patient with chronic plaque psoriasis 40 mg adalimumab every other week. 5. The method of claim 4, wherein said patient has moderate to severe chronic plaque psoriasis. 6. The method of claim 1, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 7. The method of claim 1, wherein said 40 mg adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml. 8. The method of claim 5, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 9. The method of claim 5, wherein said 40 mg adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml.

Details for Patent 8,906,373

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2039-03-29
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2039-03-29
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2039-03-29